Foley & Lardner LLP partner Louis Lehot is quoted in Law360, where he offers insight on the outlook for initial public offerings of technology companies in 2024.
Lehot said he does not expect a surge in technology IPOs this spring, given industry concerns about valuation. He noted that companies could be forced to weigh pricing concessions given investors’ current sober mood.
Lehot noted however that if interest rates do drop, thereby encouraging investors to take on more risk, and one or two technology startups go public and trade well, then IPO prospects could emerge in the year’s second half.
“You have to have one successful IPO that outperforms because it got priced at a discount,” he continued.
(Subscription required)
People
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."